MALVERN, Penn. — Endo Health Solutions on Monday announced that its Qualitest subsidiary has completed the acquisition of privately-held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash.
Boca Pharmacal is a specialty generics company that focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions.
Boca Pharmacal's commercial footprint and R&D pipeline is expected to be a strong complement to Qualitest, the company stated. The transaction will be financed with Endo's current cash on hand.